Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, today announces that following the exercise of share options by a former employee it has issued and allotted in total 126,666 new ordinary shares of 10 pence each in the Company (“Ordinary Shares”).
Application will be made for the Ordinary Shares to be admitted to trading on AIM and dealings are expected to commence on or around 21 December 2021 (“Admission”). The Ordinary Shares will rank pari passu with the existing Ordinary Shares of the Company.
Following Admission, the Company’s enlarged issued share capital will be 253,839,019. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA’s Disclosure Guidance and Transparency Rules.